

Fiscal pain, inflation, bail-out or default?

Long-term fiscal legacy of crisis and recession in advanced industrial countries


Willem H. Buiter
February 2010

Citi Investment Research & Analysis is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.




Unprecedented Fiscal Deterioration Across Industrial Countries

Pct of Global GDP In Countries With Fiscal Deficit of 10% of GDP Or More




Fiscal Balances in Industrial Countries and Emerging Markets as Pct of GDP



Debt/GDP ratios: has “risk-free” shifted to emerging markets?

Public debt/GDP in 20 emerging economies and 20 developed economies



Source: IMF, Citi Investment Research and Analysis




Unsustainable public debt is not just a Euro Area problem

General Government Debt and Deficit Indices for Selected Countries, 2009.				
(% of GDP)				
	Gross Debt	Budget Balance	Primary Balance	Cyclically Adjusted Primary Balance
Greece	114.9	-6.4	-8.2	-6.1
Portugal	83.8	-6.9	-3.9	-2.2
Spain	59.3	-12.3	-8.5	-5.8
Ireland	65.8	-12.1	-11.6	-8.4
Italy	123.6	-5.6	-0.6	1.8
Belgium	101.2	-5.9	-2.1	0.4
Austria	72.9	-4.2	-2.1	-1.0
France	84.5	-7.0	-5.3	-3.9
Germany	77.4	-4.2	-0.9	0.1
Euro Area	81.8	-6.2	-3.4	-1.2
UK	71.0	-11.6	-10.2	-7.6
Latvia	33.2	-9.0	-7.6	-5.1
Hungary	85.0	-4.1	-0.4	2.3
Romania	21.8	-7.8	-6.2	-5.5
EU	73.0	-6.9	-4.2	-2.7
USA	83.9	-12.5	-9.6	-7.8
Japan	189.3	-10.5	-6.5	-5.5
Canada	82.8	-4.9	-4.0	-2.5
Sources: IMF, Eurostat and OECD				

Massive Challenge to Return to Fiscal Sustainability

(Source: IMF)




Sovereign credit crunch in advanced industrial countries

- SCC in advanced industrial countries logical final leg of financial crisis & global downturn
 - Outlays on bail-outs of financial sector relatively minor contributor (TARP)
 - Revenue losses from crisis & recession – some of which may become permanent
 - Pay attention to structural deficits & to initial debt stocks
 - Consider long-term trends (demographics, health care financing, etc.) not captured by cyclical deficit corrections
- For many countries, largest peacetime increase in public debt burden & public sector deficits

Public debt explosions used to be a wartime thing...


US Treasury Debt as a share of GDP 1790 - 2009



Source: US Nominal and Real GDP 1790-2008: Louis D. Johnston and Samuel H. Williamson, "What Was the U.S. GDP Then?" MeasuringWorth, 2008. URL: <http://www.measuringworth.org/usgdp/>
US Treasury securities outstanding: US Treasury

Crisis and aftermath did unpleasant things to public finances


Cumulative increase in real public debt since 2007, selected countries



Source: Reinhart and Rogoff (2009)



Government debt, growth and inflation, 20 advanced economies, 1946-2009




Not much correlation between public debt and growth, except at very high debt levels

Not much correlation between debt and inflation – but for exception see next slide!

The US has historically inflated its way out of public debt traps


US Federal Government debt, GDP growth and Inflation, 1790 - 2009



Source: Reinhart and Rogoff (2009)

Surpluses, growth and inflation: three proximate drivers of changes in the public debt burden

US Treasury debt as a share of GDP and its proximate drivers since 1929



The arithmetic of debt burden reductions in the US

- How did US reduce Treasury debt to GDP ratio from 121.20% of GDP in 1946 to 31.67% of GDP in 1974?
- Arithmetically, of the 89.53 percentage points reduction in the public debt burden:
 - Inflation accounted for 52.63 percentage points
 - Real growth accounted for 55.86 percentage points
 - Interaction between real growth and inflation accounted for 1.55 percentage points
 - And Federal surpluses accounted for -20.51 percentage points
 - There were surpluses in individual years (1947, 1948, 1949, 1951, 1956, 1957, 1960, 1969)
 - The only surpluses since 1969 have been the four years 1998-2001

Sovereign indebtedness as a constraint on future bail-outs

- Surviving cross-border financial institutions may consider themselves too big to fail
- Because of the worsening public finances, they are more likely to be too big to save
- Political willingness to engage in another rescue in the next 5 to 10 years likely minimal
- The new inconsistent quartet
 1. Small open economy
 2. Large, internationally exposed banking/financial sector
 3. Own minor-league currency
 4. Limited fiscal capacity
- Ergo: the 'Iceland problem': will only large countries (with large fiscal capacities) be able to support large cross-border banks?

Historical record of sovereign default/restructuring/rescheduling

- Sovereign defaults are quite common
 - External debt
 - 1900 -2009
 - Argentina (1951, 1956, 1982, 1989, 2001)
 - Brazil (1902, 1914, 1931, 1937, 1961, 1964, 1983)
 - Mexico (1914, 1928, 1982)
 - 1945-2009
 - India (1958, 1969, 1972)
 - Indonesia (1966, 1998, 2000, 2002).
 - Poland (1981)
 - Romania (1981, 1986)
 - Russia (1991)
 - Turkey (1978, 1982)

Historical record of sovereign default/restructuring/rescheduling

- **Default on domestically held sovereign debt less common than on foreign-held debt.**
 - Abrogation of the gold clause by the US in 1933
 - Consolidation of most UK World War I debt into a perpetual annuity in 1932
 - German monetary reform in 1948
 - Croatia (1993-1996, war w. Serbia)
 - Kuwait (1991; Iraqi invasion)
 - Russia (1998-1999)
 - Ukraine (1998-2000)
 - Argentina (1982, 1989-1990 & 2002-2005)
 - Brazil (1986-1987, 1990)

Escape from serial defaulter status is possible (Brazil)!

Four policy exits from unsustainable public debt trajectories

1. Fiscal pain:

Ensure that present value of future primary (non-interest) government surpluses is at least equal to face value of the outstanding debt

Problem: fear of sovereign default raises sovereign borrowing rates (see 5-year CDS rates or 10-years spreads over Bunds). Can create explosive debt-deficit spiral

2. Bail-out ((1), (3) or (4) for someone else ...)

3. Default (moratorium, stand-still, rescheduling, restructuring, ..., repudiation)

4. Inflation

- Real value of monetary base eroded by both anticipated and unanticipated inflation
- Real value of servicing nominal interest-bearing debt only reduced by inflation surprises (unanticipated inflation tax)
- Issuing TIPs & foreign-currency denominated debt are a credible commitment against choosing an inflationary solution

5. and Growth?

Which country might choose which solution?

- Growth is (unfortunately) not a policy instrument
- Fiscal pain
 - Requires social and political cohesion/solidarity, willingness to engage in fiscal burden sharing
 - Requires political system capable of swift, radical action
- Default
 - Last resort
 - Weak governments/government institutions
 - Little social cohesion, political polarisation
 - Earlier defaults (serial defaulters)
- Inflation
 - Domestic-currency-denominated debt (preferably long-maturity and held abroad)
 - A pliable central bank (Fed less independent of Executive and Legislative branches of government than Bank of England, which is in turn less independent than the ECB).

Drivers of national policies to 'pay down' public debt


- Government capable of decisive fiscal action implies fiscal pain more likely
 - Depends on personalities, governments, institutions, social cohesion and culture
 - High: Ireland (sense of crisis) & UK (powerful executive, de-facto unicameral system + first past the post in one-member constituencies; but beware of hung Parliament)
 - Medium: Spain – disfunctional fiscal relationship between centre, autonomous regions & munis
 - Low: US – checks & balances aka gridlock; high degree of political and social polarisation
- Large private financial wealth & net external assets make fiscal pain more likely
 - High: Japan, Italy
 - Low: US, UK, Greece
- Domestic-currency-denominated debt inflation more likely
 - reinforced by
 - foreign ownership of debt
 - longer maturity
 - More of an initial stock (debt) than a flow (structural deficit) problem
- Independent monetary authority rules out inflation option
 - Especially relevant in Eurozone (Greece, Ireland, Spain, Italy).
- Exchange rate & balance sheet consequences of sharp currency depreciation make inflation option unattractive in UK
- Large private nominal debt stocks (internally and/or externally held) may make inflation solution more attractive

Reserve currency status of US\$ & the 3 public debt reduction options

- Anticipated inflation tax falls largely on foreign holders of \$ currency (60-70% of total US currency stock (around \$950 bn) held abroad)
- Unanticipated inflation tax falls to significant extent on foreign owners (at least 40% of US Treasuries held abroad – about \$3.2 trillion out of \$7.9 trillion at end of 2009)
- But: if sharp reduction in purchasing power and external value of US\$ were to cause lasting reduction in demand for US\$ currency and US\$-denominated debt (and/or raise interest rates materially & lastingly), loss of future external seigniorage & other future benefits from ‘exorbitant privilege’ could act as deterrent.
- Old reserve currencies don’t die, they just fade away....
- But...reserve currency status of US\$ could be materially affected by burst of inflation & exchange rate depreciation

Eurozone fiscal problems are long-standing

10-year government bond spread vs Bunds 1996-2010




- Inflation and exchange rate depreciation driving spreads over Bunds before EMU
- A lull from 1999/2001 to 2007
- Sovereign default risk driving spreads over Bunds in EMU after 2007

Can Greece be bailed?


Greece is small...

Share of 2009 Euro Area GDP (%)



...very small

Share of EU GDP (%)



Default of Eurozone sovereign \neq break-up of Euro Area

- Would sovereign default be more or less costly out of the Euro Area?
 - Existing stock of debt: no difference
 - New borrowing: more costly out of the Euro Area
 - Competitiveness gain: short-term gain out of the Euro Area
 - Balance sheet disruption for private sector: worse out of the Euro Area
- No Euro Area or EU fiscal support out of the Euro Area
- Out of the Eurozone means out of the EU (Acquis! See Athanassiou (2009))
- A country cannot be expelled from the Eurozone (or the EU)
- Only real threat to Euro Area integrity is if the strongest members (Germany) were to leave
- Any rational would-be sovereign defaulter would stay in the Euro Area
 - Risks:
 - Errors/misunderstandings among fragile sovereigns, EU and IMF
 - Populist/nationalist temporary irrationality in fragile states
 - Too large to save (Spain & Italy vs Greece, Portugal & Ireland)

Conclusions

- Current fiscal problems of advanced industrial countries unprecedented in peace time
- Fiscal sustainability can be undermined by economic shocks, political developments or 'acts of God' – wars, natural disasters etc.
- Most countries will, eventually, choose fiscal pain option for eliminating unsustainable public sector debt and deficits
- “Growing your way out of excessive debt” is not a plausible option for advanced industrial countries
- Inflationary solution unlikely in advanced industrial countries, but not impossible
- Sovereign default highly unlikely in advanced industrial countries, but not impossible
- Bail out more likely than default in Eurozone/EU
- Too large to save problem exists but overstated in Eurozone
- (Threat of) sovereign default in Eurozone member state will not make that country more likely to leave Eurozone

References

- Reinhart, Carmen and Kenneth Rogoff (2009), “Growth in a time of debt”, *American Economic Association, Papers and Proceedings*, forthcoming.
- Athanassiou, Phoebus (2009), “Withdrawal and Expulsion from the EU and EMU”, European Central Bank Legal Working Paper Series No. 10, December 2009.

Appendix A-1

Analyst Certification

Each research analyst(s) primarily responsible for the preparation and content of all or any identified portion of this research report hereby certifies that, with respect to each issuer or security or any identified portion of the report with respect to an issuer or security that the research analyst covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this research report.

IMPORTANT DISCLOSURES

Rohini Malkani has in the past worked with the India government or its divisions in her personal capacity.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research & Analysis product ("the Product"), please contact Citi Investment Research & Analysis, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Ltd

Willem H Buiters

OTHER DISCLOSURES

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research & Analysis (CIRA) does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of CIRA to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers: Morgan Stanley & Co. Incorporated (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Investment Research & Analysis (CIRA) research report. Ask your Financial Advisor or use smithbarney.com to view any available Morgan Stanley research reports in addition to CIRA research reports.

Important disclosure regarding the relationship between the companies that are the subject of this CIRA research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

The required disclosures provided by Morgan Stanley and Citigroup Global Markets, Inc. on Morgan Stanley and CIRA research relate in part to the separate businesses of Citigroup Global Markets, Inc. and Morgan Stanley that now form Morgan Stanley Smith Barney LLC, rather than to Morgan Stanley Smith Barney LLC in its entirety. For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citigroupgeo.com/geopublic/Disclosures/index_a.html.

This CIRA research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of CIRA. This could create a conflict of interest.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product is made available in France by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in Italy by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Foro Buonaparte 16, Milan, 20121, Italy. The Product is made available in Japan by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by Nikko Cordial Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de

Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd. (Company Number 604457), a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 Lambton Quay, Wellington. The Product is made available in Pakistan by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul. Chalubinskiego 8, 00-630 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Spain by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gassef, 4th Floor, Madrid, 28006, Spain. The Product is made available in Taiwan through Citigroup Global Markets Taiwan Securities Company Ltd., which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in Turkey through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the U.A.E, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different CIRA ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to CIRA's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

© 2010 Citigroup Global Markets Inc. Citi Investment Research & Analysis is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley

Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST